Study summary

An antibody-drug conjugate plus immunotherapy beat chemo plus immunotherapy as first treatment

ASCENT-04 trial (sacituzumab govitecan plus pembrolizumab) · 443 people, phase 3 · Published January 2026, New England Journal of Medicine

11.2months without progression, vs 7.8 with chemo plus pembrolizumab

What was tested

Sacituzumab govitecan plus pembrolizumab against chemotherapy plus pembrolizumab, as first treatment for advanced PD-L1-positive TNBC.

What they found

What it means

Likely to become a first choice for advanced PD-L1-positive TNBC.

N Engl J Med, via PubMed ↗ Trial record NCT05382286 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.